Serum immunoregulatory proteins as predictors of overall survival of metastatic melanoma patients treated with ipilimumab

Yoshinobu Koguchi, Helena M. Hoen, Shelly A. Bambina, Michael D. Rynning, Richard K. Fuerstenberg, Brendan D. Curti, Walter J. Urba, Christina Milburn, Frances Bahjat, Alan J. Korman, Keith S. Bahjat

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Treatment with ipilimumab improves overall survival (OS) in patients with metastatic melanoma. Because ipilimumab targets T lymphocytes and not the tumor itself, efficacy may be uniquely sensitive to immunomodulatory factors present at the time of treatment. We analyzed serum from patients with metastatic melanoma (247 of 273, 90.4%) randomly assigned to receive ipilimumab or gp100 peptide vaccine. We quantified candidate biomarkers at baseline and assessed the association of each using multivariate analyses. Results were confirmed in an independent cohort of similar patients (48 of 52, 92.3%) treated with ipilimumab. After controlling for baseline covariates, elevated chemokine (C-X-C motif) ligand 11 (CXCL11) and soluble MHC class I polypeptide-related chain A (sMICA) were associated with poor OS in ipilimumab-treated patients [log10 CXCL11: HR, 1.88; 95% confidence interval (CI), 1.14- 3.12; P = 0.014; and log10 sMICA quadratic effect P = 0.066; sMICA (≥ 247 vs. 247): HR, 1.75; 95% CI, 1.02-3.01]. Multivariate analysis of an independent ipilimumab-treated cohort confirmed the association between log10 CXCL11 and OS (HR, 3.18; 95% CI, 1.13-8.95; P = 0.029), whereas sMICA was less strongly associated with OS [log10 sMICA quadratic effect P = 0.16; sMICA (≥247 vs. 247): HR, 1.48; 95% CI, 0.67-3.27]. High baseline CXCL11 and sMICA were associated with poor OS in patients with metastatic melanoma after ipilimumab treatment but not vaccine treatment. Thus, pretreatment CXCL11 and sMICA may represent predictors of survival benefit after ipilimumab treatment as well as therapeutic targets.

Original languageEnglish (US)
Pages (from-to)5084-5092
Number of pages9
JournalCancer Research
Volume75
Issue number23
DOIs
StatePublished - Dec 1 2015
Externally publishedYes

Fingerprint

Blood Proteins
Melanoma
Peptides
Survival
Confidence Intervals
Ligands
Chemokine CCL11
Therapeutics
Multivariate Analysis
Subunit Vaccines
ipilimumab
Vaccines
Biomarkers
T-Lymphocytes
Serum
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Koguchi, Y., Hoen, H. M., Bambina, S. A., Rynning, M. D., Fuerstenberg, R. K., Curti, B. D., ... Bahjat, K. S. (2015). Serum immunoregulatory proteins as predictors of overall survival of metastatic melanoma patients treated with ipilimumab. Cancer Research, 75(23), 5084-5092. https://doi.org/10.1158/0008-5472.CAN-15-2303

Serum immunoregulatory proteins as predictors of overall survival of metastatic melanoma patients treated with ipilimumab. / Koguchi, Yoshinobu; Hoen, Helena M.; Bambina, Shelly A.; Rynning, Michael D.; Fuerstenberg, Richard K.; Curti, Brendan D.; Urba, Walter J.; Milburn, Christina; Bahjat, Frances; Korman, Alan J.; Bahjat, Keith S.

In: Cancer Research, Vol. 75, No. 23, 01.12.2015, p. 5084-5092.

Research output: Contribution to journalArticle

Koguchi, Y, Hoen, HM, Bambina, SA, Rynning, MD, Fuerstenberg, RK, Curti, BD, Urba, WJ, Milburn, C, Bahjat, F, Korman, AJ & Bahjat, KS 2015, 'Serum immunoregulatory proteins as predictors of overall survival of metastatic melanoma patients treated with ipilimumab', Cancer Research, vol. 75, no. 23, pp. 5084-5092. https://doi.org/10.1158/0008-5472.CAN-15-2303
Koguchi, Yoshinobu ; Hoen, Helena M. ; Bambina, Shelly A. ; Rynning, Michael D. ; Fuerstenberg, Richard K. ; Curti, Brendan D. ; Urba, Walter J. ; Milburn, Christina ; Bahjat, Frances ; Korman, Alan J. ; Bahjat, Keith S. / Serum immunoregulatory proteins as predictors of overall survival of metastatic melanoma patients treated with ipilimumab. In: Cancer Research. 2015 ; Vol. 75, No. 23. pp. 5084-5092.
@article{3e1f77b9aeef4ed185d25ad5c4694638,
title = "Serum immunoregulatory proteins as predictors of overall survival of metastatic melanoma patients treated with ipilimumab",
abstract = "Treatment with ipilimumab improves overall survival (OS) in patients with metastatic melanoma. Because ipilimumab targets T lymphocytes and not the tumor itself, efficacy may be uniquely sensitive to immunomodulatory factors present at the time of treatment. We analyzed serum from patients with metastatic melanoma (247 of 273, 90.4{\%}) randomly assigned to receive ipilimumab or gp100 peptide vaccine. We quantified candidate biomarkers at baseline and assessed the association of each using multivariate analyses. Results were confirmed in an independent cohort of similar patients (48 of 52, 92.3{\%}) treated with ipilimumab. After controlling for baseline covariates, elevated chemokine (C-X-C motif) ligand 11 (CXCL11) and soluble MHC class I polypeptide-related chain A (sMICA) were associated with poor OS in ipilimumab-treated patients [log10 CXCL11: HR, 1.88; 95{\%} confidence interval (CI), 1.14- 3.12; P = 0.014; and log10 sMICA quadratic effect P = 0.066; sMICA (≥ 247 vs. 247): HR, 1.75; 95{\%} CI, 1.02-3.01]. Multivariate analysis of an independent ipilimumab-treated cohort confirmed the association between log10 CXCL11 and OS (HR, 3.18; 95{\%} CI, 1.13-8.95; P = 0.029), whereas sMICA was less strongly associated with OS [log10 sMICA quadratic effect P = 0.16; sMICA (≥247 vs. 247): HR, 1.48; 95{\%} CI, 0.67-3.27]. High baseline CXCL11 and sMICA were associated with poor OS in patients with metastatic melanoma after ipilimumab treatment but not vaccine treatment. Thus, pretreatment CXCL11 and sMICA may represent predictors of survival benefit after ipilimumab treatment as well as therapeutic targets.",
author = "Yoshinobu Koguchi and Hoen, {Helena M.} and Bambina, {Shelly A.} and Rynning, {Michael D.} and Fuerstenberg, {Richard K.} and Curti, {Brendan D.} and Urba, {Walter J.} and Christina Milburn and Frances Bahjat and Korman, {Alan J.} and Bahjat, {Keith S.}",
year = "2015",
month = "12",
day = "1",
doi = "10.1158/0008-5472.CAN-15-2303",
language = "English (US)",
volume = "75",
pages = "5084--5092",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "23",

}

TY - JOUR

T1 - Serum immunoregulatory proteins as predictors of overall survival of metastatic melanoma patients treated with ipilimumab

AU - Koguchi, Yoshinobu

AU - Hoen, Helena M.

AU - Bambina, Shelly A.

AU - Rynning, Michael D.

AU - Fuerstenberg, Richard K.

AU - Curti, Brendan D.

AU - Urba, Walter J.

AU - Milburn, Christina

AU - Bahjat, Frances

AU - Korman, Alan J.

AU - Bahjat, Keith S.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Treatment with ipilimumab improves overall survival (OS) in patients with metastatic melanoma. Because ipilimumab targets T lymphocytes and not the tumor itself, efficacy may be uniquely sensitive to immunomodulatory factors present at the time of treatment. We analyzed serum from patients with metastatic melanoma (247 of 273, 90.4%) randomly assigned to receive ipilimumab or gp100 peptide vaccine. We quantified candidate biomarkers at baseline and assessed the association of each using multivariate analyses. Results were confirmed in an independent cohort of similar patients (48 of 52, 92.3%) treated with ipilimumab. After controlling for baseline covariates, elevated chemokine (C-X-C motif) ligand 11 (CXCL11) and soluble MHC class I polypeptide-related chain A (sMICA) were associated with poor OS in ipilimumab-treated patients [log10 CXCL11: HR, 1.88; 95% confidence interval (CI), 1.14- 3.12; P = 0.014; and log10 sMICA quadratic effect P = 0.066; sMICA (≥ 247 vs. 247): HR, 1.75; 95% CI, 1.02-3.01]. Multivariate analysis of an independent ipilimumab-treated cohort confirmed the association between log10 CXCL11 and OS (HR, 3.18; 95% CI, 1.13-8.95; P = 0.029), whereas sMICA was less strongly associated with OS [log10 sMICA quadratic effect P = 0.16; sMICA (≥247 vs. 247): HR, 1.48; 95% CI, 0.67-3.27]. High baseline CXCL11 and sMICA were associated with poor OS in patients with metastatic melanoma after ipilimumab treatment but not vaccine treatment. Thus, pretreatment CXCL11 and sMICA may represent predictors of survival benefit after ipilimumab treatment as well as therapeutic targets.

AB - Treatment with ipilimumab improves overall survival (OS) in patients with metastatic melanoma. Because ipilimumab targets T lymphocytes and not the tumor itself, efficacy may be uniquely sensitive to immunomodulatory factors present at the time of treatment. We analyzed serum from patients with metastatic melanoma (247 of 273, 90.4%) randomly assigned to receive ipilimumab or gp100 peptide vaccine. We quantified candidate biomarkers at baseline and assessed the association of each using multivariate analyses. Results were confirmed in an independent cohort of similar patients (48 of 52, 92.3%) treated with ipilimumab. After controlling for baseline covariates, elevated chemokine (C-X-C motif) ligand 11 (CXCL11) and soluble MHC class I polypeptide-related chain A (sMICA) were associated with poor OS in ipilimumab-treated patients [log10 CXCL11: HR, 1.88; 95% confidence interval (CI), 1.14- 3.12; P = 0.014; and log10 sMICA quadratic effect P = 0.066; sMICA (≥ 247 vs. 247): HR, 1.75; 95% CI, 1.02-3.01]. Multivariate analysis of an independent ipilimumab-treated cohort confirmed the association between log10 CXCL11 and OS (HR, 3.18; 95% CI, 1.13-8.95; P = 0.029), whereas sMICA was less strongly associated with OS [log10 sMICA quadratic effect P = 0.16; sMICA (≥247 vs. 247): HR, 1.48; 95% CI, 0.67-3.27]. High baseline CXCL11 and sMICA were associated with poor OS in patients with metastatic melanoma after ipilimumab treatment but not vaccine treatment. Thus, pretreatment CXCL11 and sMICA may represent predictors of survival benefit after ipilimumab treatment as well as therapeutic targets.

UR - http://www.scopus.com/inward/record.url?scp=84955285589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955285589&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-15-2303

DO - 10.1158/0008-5472.CAN-15-2303

M3 - Article

VL - 75

SP - 5084

EP - 5092

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 23

ER -